IMPROVING RECRUITMENT TO PHARMACOLOGICAL TRIALS FOR ILLICIT OPIOID USE: FINDINGS FROM A QUALITATIVE FOCUS GROUP STUDY

Joanne Neale (Corresponding author)
Professor of Addictions Qualitative Research, National Addiction Centre, King’s College London, United Kingdom
Conjoint Professor, Centre for Social Research in Health, University of New South Wales Sydney, Australia

Charlotte N. E. Tompkins
Post-doctoral Research Worker, National Addiction Centre, King’s College London, United Kingdom

Rebecca McDonald
Post-doctoral Research Associate, National Addiction Centre, King’s College London, United Kingdom

Professor Sir John Strang
Professor of the Addictions, National Addiction Centre, King’s College London, United Kingdom

RUNNING HEAD:
RECRUITMENT TO TRIALS OF PHARMACOLOGICAL INTERVENTIONS FOR ILLICIT OPIOID USE

WORD COUNT: 4,109
CONFLICT OF INTEREST/ DISCLOSURES

JN receives honoraria and some expenses from *Addiction* journal in her role as Commissioning Editor and Senior Qualitative Editor. JS is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service-providers. He has also worked with a range of governmental and non-governmental organisations, and with pharmaceutical companies to seek to identify new or improved treatments from whom he and his employer (King’s College London) have received honoraria, travel costs and/or consultancy payments. This includes work with, during past 3 years, Martindale, Indivior, MundiPharma, Braeburn/Camurus and trial medication supply from iGen and from Camurus. His employer (King’s College London) has registered intellectual property on a novel buccal naloxone formulation and he has also been named in a patent registration by a Pharma company regarding a concentrated nasal naloxone spray. For a fuller account, see JS’s webpage at [http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx](http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx) RM has undertaken an unpaid student industry placement with MundiPharma Research Ltd. RM and JS have both worked as consultants for the United Nations Office on Drugs and Crime (UNODC). CNET has no disclosures to report.

ACKNOWLEDGEMENTS

We would like to thank all focus group participants and the services that helped us with the research. We would also like to acknowledge the Pilgrim Trust and MundiPharma for co-funding the study. Joanne Neale is part-funded by, and John Strang is supported by, the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. JS is a NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the Pilgrim Trust or MundiPharma.
IMPROVING RECRUITMENT TO PHARMACOLOGICAL TRIALS FOR ILLICIT OPIOID USE: FINDINGS FROM A QUALITATIVE FOCUS GROUP STUDY

ABSTRACT

**Aim:** To explore potential study participants’ views on willingness to join clinical trials of pharmacological interventions for illicit opioid use to inform and improve future recruitment strategies.

**Design:** Qualitative focus group study (6 groups: oral methadone [2 groups]; buprenorphine tablets [2 groups]; injectable opioid agonist treatment [1 group]; and former opioid agonist treatment [1 group]).

**Settings:** Drug and alcohol services and a peer support recovery service (London, United Kingdom).

**Participants:** 40 people with experience of opioid agonist treatment for heroin dependence (26 males, 14 females; ages 33-66 years).

**Measurements:** Data collection was facilitated by a topic guide that explored willingness to enrol in clinical pharmacological trials. Groups were audio-recorded and transcribed. Transcribed data were analysed inductively via Iterative Categorisation.

**Findings:** Participants’ willingness to join pharmacological trials of medications for opioid dependence was affected by factors relating to study burden, study drug, study design, study population, and study relationships. Participants worried that the trial drug might be worse than, or interfere with, their current treatment. They also misunderstood aspects of trial design despite the researchers’ explanations.

**Conclusions:** Recruitment of participants for clinical trials of pharmacological interventions for illicit opioid use could be improved if researchers became better at explaining clinical trials to potential participants, dispelling misconceptions about trials, and increasing trust in the research process and research establishment. A checklist of issues to consider when designing pharmacological trials for illicit opioid use is proposed.

**Key words:** Qualitative study; clinical trials; pharmacological interventions; opioid dependence; study recruitment; opioid agonist treatment; ethics
IMPROVING RECRUITMENT TO PHARMACOLOGICAL TRIALS FOR ILLICIT OPIOID USE: FINDINGS FROM A QUALITATIVE INTERVIEW STUDY

INTRODUCTION

Pharmacological interventions play a critical role in the treatment of illicit opioid use. In 1964, methadone was first tested as a long-term maintenance treatment in two patients previously maintained on morphine\(^1\)\(^-\)\(^3\). Methadone subsequently became the dominant medical treatment for opioid dependence\(^4\), but the search for alternative and more effective medications has continued. Over the years, different drugs and drug combinations (naltrexone, buprenorphine, combined buprenorphine and naloxone, levo-alpha acetyl methadol, morphine, dihydrocodeine), as well as different dosing regimes (detoxification, reduction, maintenance) and formulations (liquids, tablets, implants, injectables), have emerged. In response to rapid global increases in opioid use and poor adherence to existing opioid medications\(^5\), novel long-acting formulations (e.g. slow-release implants, depot injections) are also now being developed.

Before new opioid medications receive regulatory approval, they need to be tested in clinical trials, including volunteer Phase 1 studies as well as randomized controlled trials (RCTs) with opioid-dependent patients, to demonstrate safety and efficacy\(^6\). Difficulties recruiting participants to RCTs are common within most medical research\(^7\)\(^,\)\(^8\); indeed, one review of RCTs across a range of medical conditions found that nearly half received an extension due to recruitment problems\(^9\). Many addiction trials have also reported problems achieving their target sample sizes or taking longer to recruit than planned\(^10\)\(^-\)\(^14\). According to one review, less than 45 out of every 100 potential participants in drug dependence RCTs were actually eligible, consented and did not drop out immediately after randomization\(^12\).

Researchers conducting trials of both pharmacological and psychosocial interventions for alcohol and other drug problems have sometimes published details of their recruitment difficulties. These data indicate that substance users can be deterred from participating in addiction trials because they do not like or cannot meet the conditions of treatment, such as having to attend appointments and services daily\(^11\); lack understanding of, or dislike, research\(^10\)\(^,\)\(^12\); have low motivation for treatment\(^10\)\(^,\)\(^14\); worry about their confidentiality,
privacy or lack of choice as trial participants\textsuperscript{10}; are reluctant to be a ‘guinea pig’ or part of an ‘experiment’\textsuperscript{10}; and are concerned about being assigned to a placebo treatment\textsuperscript{14,15} or control condition\textsuperscript{10}.

In addition, recruitment to alcohol and other drug trials can be hampered because clinic staff have insufficient interest, time or capacity to conduct the research\textsuperscript{10,14,16,17}; forget or become confused by complicated entry criteria and so do not refer patients to the trial\textsuperscript{14}; and do not understand or are sceptical about the research or the trial drug\textsuperscript{10,17,18}. Other recruitment challenges are more practical, such as strict eligibility criteria that limit the pool of potential participants\textsuperscript{10-13,19}; fewer potential participants than expected or needed in a particular area or service\textsuperscript{10,13}; and difficulty contacting potential participants because they lack stable accommodation, move around, or change telephone numbers\textsuperscript{13,20}.

Responding to these problems, addiction researchers have already identified strategies that can be incorporated into their RCT designs to facilitate and enhance recruitment. These include offering financial reimbursements or incentives\textsuperscript{14}; providing non-monetary incentives, such as coffee or bus tokens\textsuperscript{21}; increasing the odds of receiving the experimental treatment\textsuperscript{10}; simplifying the study referral processes\textsuperscript{10,14}; providing treatments which appeal to the target population or are otherwise unavailable\textsuperscript{13}; sending appointment reminders\textsuperscript{10,14}; inviting trial participants to recruit others from their social networks\textsuperscript{22}; highlighting the potential benefits of the study to patients and staff\textsuperscript{14}; and engaging with peer and community organisations to secure their commitment to the research\textsuperscript{13,21,22}.

Very few studies have, however, asked people who are dependent on drugs or alcohol for their views on clinical trial participation. A rare exception is a quantitative survey of 1,020 illicit drug users recruited from community settings in Canada. This research identified high rates of willingness to participate in a pharmacological addiction treatment trial (58.3%), with those engaged in high-risk drug and sexual activities expressing greater willingness\textsuperscript{23}. In addition, a qualitative study of 37 African American crack cocaine users already enrolled in three different behavioural HIV prevention studies found that decisions to participate in HIV-related research (two behavioural interventions and a hepatitis vaccine project) were affected by the desire for information; scepticism and mistrust of research and researchers; perceptions of medical care and monitoring within the study; and participant control over decisions to enrol or not\textsuperscript{24}. 
Lastly, a Belgian study of 52 heroin users who were eligible for, but not recruited to, a heroin-assisted treatment trial concluded that non-enrolment related to the trial conditions and fear of becoming more dependent because of the trial treatment\(^{[11]}\). The data were, however, quantitative, descriptive and related to one specific heroin-assisted treatment trial. Qualitative research is particularly suited to providing detailed insights into how and why people who use substances think and act as they do and has often been used, in related areas, to investigate drug treatment and its effectiveness\(^{[25]}\). Despite this, we are aware of no qualitative studies of recruitment to clinical trials of pharmacological interventions for illicit opioid use. The aim of our study was to explore potential study participants’ views on willingness to join such trials in order to inform and improve future recruitment strategies.

**METHODS**

Data were collected via six focus groups (FGs) conducted with 40 people who were currently being treated, or who had previously been treated, with opioid agonist treatment (OAT) for heroin dependence (26 males, 14 females; ages 33-66 years). Groups were deliberately stratified by treatment drug and treatment status to prevent participants comparing their own treatment with other treatments and then becoming dissatisfied. The groups were: oral methadone (2 groups); buprenorphine tablets (2 groups); injectable OAT (1 group); and former OAT (1 group). Each group comprised 4-8 participants (see Table 1 for additional participant details). The study received ethical approval from the United Kingdom (UK) NHS Research Ethics Service.

**TABLE 1**

The groups were conducted in drug and alcohol services and a peer support recovery service in London, UK, during March and April 2017. To optimise recruitment, posters with the researchers’ contact details were displayed in the services; researchers approached potential participants in person at the services; workers encouraged service users to contact the researchers; and participants from the earlier focus groups introduced the research to their peers (‘snowball sampling’). Everyone who expressed interest in taking part (n=75) answered a simple screening questionnaire that covered gender, age, ethnicity, substance use,
prescribed medications, and contact details. The researchers then used the screening information to identify and invite up to 10 people (both sexes and different ethnic backgrounds but with the same current medication) to each group.

Data collection was facilitated by two researchers who used a topic guide to gently steer the discussions whilst also allowing participants to raise issues spontaneously. The guide focused on participants’ willingness to join clinical trials of pharmacological interventions for illicit opioid dependence, including factors that might encourage or discourage participation. The researchers gave verbal explanations of trial methodology and presented three example study designs to increase participants’ understanding and encourage discussion around technical issues, such as randomization, blinding, and placebo treatment. The researchers also answered participants’ questions. Groups were audio-recorded and participants were offered refreshments and £10 as a gesture of thanks.

The audio recordings lasted 44-64 minutes and were transcribed verbatim by a professional transcriber. All transcribed data were then analysed inductively through a process of Iterative Categorisation[26]. No specialist coding software or deductive codes were used. First, each focus group was analysed in isolation within Microsoft Word. To this end, each transcription was reviewed line by line by the lead author to identify recurrent themes in the data. These themes were then grouped into categories, discussed within the team, and summarised in a new Word document. This process enabled us to a) capture the nature of the discussion within each group, including the extent to which participants agreed or disagreed with each other and b) assess whether the themes and categories identified were similar across the groups.

In practice, there were some differences of opinion between participants within individual groups but no notable differences of opinion when findings were compared across the groups. For example, within groups participants debated and often failed to agree on whether or not opioid users would participate in a trial without financial compensation. However, this same debate and lack of agreement was replicated across groups. Meanwhile, the themes and categories identified within each group were very similar, but not exactly the same across groups (an unsurprising outcome given that the focus group facilitators had used the topic guide flexibly and encouraged free discussion within each group). In order to capture the full spectrum of responses, we therefore merged the themes from each of the six groups into a
Further Word document and then re-reviewed, re-ordered and re-categorised the themes inductively. By the end of this process, all identified themes had been categorised under one of five headings: 1. Study burden; 2. Study drug; 3. Study design; 4. Study population; and 5. Study relationships. Findings are presented descriptively and then reviewed more critically in the Discussion.

FINDINGS

1. Study burden

Participants reported that their willingness to join a clinical trial of an opioid medication would be undermined if involvement created too many demands for them (see Table 2). In particular, they felt that the financial costs of travel to and from a trial site, as well as the physical difficulty of travelling with pre-existing health and mobility problems, were important barriers to participation. Some emphasized that travel could leave them feeling exhausted, so limiting their ability to undertake other activities for the rest of the day. Others complained that trials requiring daily travel to a study site, or the completion of multiple tasks each time they attended a study site, were especially demanding.

Generally, participants believed that current and former heroin users would be reluctant to join trials if they had to provide blood samples since poor venous access could make this difficult. Moreover, needles could trigger a desire to inject. In addition, some expressed concerns that urine drug screening was intrusive and positive test results could have negative consequences for them (e.g. existing treatment might be altered, reduced or stopped). Participants also tended to report that studies lasting longer than one month were less acceptable since they locked people into treatment, limited treatment flexibility and choice, and potentially interfered with people’s own treatment goals by, for example, precluding the option of abstinence.

Despite these concerns, participants suggested various ways that the burden of trial participation might be reduced. For example, many indicated that they would be more likely to enrol in a trial if the study site was near to where they lived, as this reduced their travel and associated costs. Some also suggested that study medications could be brought to their homes.
or dispensed via a mobile treatment van. Most participants felt that researchers should provide travel passes or a taxi to take them to the study site and, at the very least, reimburse all travel costs. Offering flexibility in terms of when people could attend for treatment and posting any questionnaires to them for home completion were also proposed as ways of making participation less arduous. Finally, participants frequently argued that trials should be as short as possible (ideally less than a month).

TABLE 2

2. Study drug

Anxieties about the pharmacology of the study drug, with particular concerns that it might cause withdrawal symptoms, also seemed to discourage trial participation (see Table 3). Withdrawal symptoms were almost universally feared on the grounds that they were distressing, could prompt former heroin users to relapse, and might expose pain that had previously been masked by opioids. Some participants argued that they would be reluctant to join pharmacological trials because they would be afraid of how a study drug might interact with any other medications they were taking or because of previous bad experiences after taking street or prescribed drugs. Indeed, some said that they would not personally participate in a trial under any circumstances if they did not like, or had heard bad things about, the trial drug. Meanwhile, nearly all emphasized that they would not join first-in-human trials because of the lack of evidence on the medication and its side effects.

Participants nonetheless volunteered strategies that researchers could deploy to mitigate their anxieties. For example, some explained that they would be more willing to participate in a trial, even if withdrawal symptoms might occur, if they were reassured that they would have access to their own ‘regular’ opioid medications; offered a special supply of ‘rescue opioids’; given some control over the study dose; or promised direct and immediate access to medical care. Participants also often stated that having clear information about the trial drug might allay concerns. Specifically, they wanted to know the chemical structure of the trial drug, potential side effects, and how it had performed in any animal or first-in-human studies. Participants additionally reported greater willingness to enrol in a trial if they had written
agreement, a formal ‘contract’, or a note on their medical records that confirmed they could leave the trial and return to their previous medication at any time.

TABLE 3

3. Study design

Aspects of the study design were also identified as barriers to recruitment (see Table 4). Participants occasionally reported that they would not enrol in a trial if the aim was unclear or if they thought that the study would not recruit. Others stated that they would be reluctant to participate if they believed that those recruited would be able to supplement the trial medication with illicit drugs, so compromising the study results. Participants also frequently questioned the feasibility of giving opioid users placebo drugs or blinding them to treatment given that people who are dependent on opioids know the effects and side effects of opioid medications and would recognise if they were receiving a different drug.

Overall, participants were negative about randomization and blinding, arguing that they disliked not knowing what medication they would be receiving, the lack of choice, and not feeling in control. Crucially, not knowing one’s medication meant that they could not assess the likelihood that they would experience withdrawal symptoms or other adverse reactions, their ability to receive pain relief in the event of an accident, or how they would feel more generally. Other participants reported that they would not enrol in a trial if there was uncertainty about the length of time it would take to return to their pre-trial medication once the study ended or if the trial required them to attend services where staff had previously exhibited negative or stigmatizing attitudes towards them.

Yet again, however, participants provided suggestions on how trials might be improved to increase recruitment. Most reported that current and former heroin users would be more willing to join a trial if the rationale for, and processes of, blinding and randomization were clearly explained. Some also stated that they would be more prepared to participate in studies (particularly those likely to induce withdrawal symptoms) if they took place in a safe, comfortable, controlled environment, such as a hospital, where there were activities (e.g. play
stations and television), nurses or medical staff, round-the-clock monitoring, and alternative medications if the treatment drug did not work. Lastly, one participant reported that she would be more likely to join a trial if she had reassurance that she would still be able to see her keyworker as usual.

### TABLE 4

**4. Study population**

Participants emphasized that readiness to join a clinical drug trial would invariably be influenced by an individual’s treatment status prior to study enrolment (see Table 5). For example, most agreed that former heroin users who were happy with their current treatment would be less likely to enrol in a medication trial as they would not want to jeopardize a treatment that was already working for them, particularly if they had struggled to secure the treatment and were now stable and not using illicit drugs. In contrast, participants generally felt that opioid users would be more likely to participate in a trial if they were dissatisfied with their current treatment, thought that the trial treatment might be preferable to their current treatment, or were desperate for treatment.

### TABLE 5

**5. Study relationships**

Lastly, participants reported that lack of trust in people, systems and organisations associated with drug trials would discourage study enrolment (see Table 6). In particular, they emphasized their distrust of the pharmaceutical industry, noting how pharmaceutical companies make mistakes when conducting research and yet still generate ‘huge’ profits. Some participants also highlighted their mistrust of doctors and the addiction treatment system, adding that service providers are constantly changing, the treatment system is unstable, and they would be reluctant trust anyone who promised them that their medication
would be re-instated if they left a trial. Beyond this, there was a general concern that their personal details might be passed on to others not involved in the research.

Participants nonetheless identified ways that relationships with those conducting trials might be improved. For example, some reported that involving current and former heroin users in the design of a study would increase willingness to participate as it demonstrated that researchers were receptive to their views. Participants also felt that they might be encouraged to join a study after listening to peers or clinicians who were enthusiastic about the trial. Above all else, however, participants stressed the importance of cash incentives, explaining that these put them into a more formal contractual relationship with researchers but also showed that researchers valued their input. Indeed, some thought that cash payments were essential given that trials could not occur without current or former heroin users, that participant reimbursement for opioid dependence trials should match reimbursement for other industry-sponsored trials, and that the payment level should depend on the risks and discomfort likely to be experienced.

Although cash incentives were nearly always preferred, some participants still felt that non-cash payments (e.g. store vouchers, transport passes, food vouchers or gym memberships) were effective forms of incentivisation and recognition, especially if study participants could choose the type of non-cash payment received. In addition, some suggested that promising current heroin users a fast track into treatment, or a place in residential treatment, on completion of the trial might increase recruitment. Lastly, a small number of participants stated that they would be prepared to join a trial without any compensation at all in order to help others; specifically, they wanted to contribute to research, facilitate better future treatment options, and help save lives.

TABLE 6

DISCUSSION

We conducted a small qualitative study that focused on recruitment to trials of pharmacological interventions for illicit opioid dependence. Data collection was narrow in
scope and only involved people who had received OAT for heroin use. The analyses undertaken were exploratory and caution should therefore be taken in generalizing from the findings. Despite this, themes identified supported international research on factors that hinder and facilitate recruitment to trials of both pharmacological and psychosocial addiction interventions. For example, participants reported that study enrolment was deterred by the burden and conditions of involvement\[^{11,20}\]; concerns about confidentiality\[^{10}\]; mistrust of researchers\[^{24}\]; and reluctance to be a treatment ‘guinea pig’\[^{10}\]. In contrast, recruitment was encouraged by access to study information\[^{24}\]; the presence of medical care and monitoring\[^{24}\]; treatments being desirable\[^{13}\]; and reimbursements or incentives\[^{14,21}\].

Findings were not, however, entirely consistent with previous research. Participants did not express concerns about the placebo or control condition\[^{10,14,15}\]; instead they were more anxious about the treatment drug. They also did not seem to be worried by limited trial duration\[^{11}\]; on the contrary, they recommended that trials should be as short as possible. Other issues that concerned the participants have not been well-documented previously, including the side effects of the study drug (especially withdrawal symptoms and interactions with other medications); perceived weaknesses in the trial design (uncertainty about the aim, feasibility, randomization, blinding, setting and post-trial procedures); already being satisfied with, or making good progress on, a current medication; and lack of trust in the pharmaceutical industry and treatment system. In short, participants worried that the trial drug might be worse than their current treatment; a reminder that people already receiving medication for heroin dependence will likely have different concerns about trial participation than those not currently in treatment.

Crucially, participants also made some observations about clinical trials that seemed to be confused or misinformed. For example, many expressed concerns about having to take drugs with unknown effects, being trapped in trials without being able to leave, having a pre-existing valued treatment disrupted, and not knowing what would happen to them once the trial finished. In practice, of course, trial protocols are carefully reviewed by funders and ethics committees and subsequently scrutinized by trial steering committees. Furthermore, all patients are given detailed information about the trial procedures and medication, and patient safety and confidentiality are paramount. Nevertheless, the concerns expressed by our participants were substantial. They additionally suggested that recruitment could be improved by restricting studies to less than a month in duration, allowing them to have control over the
study drug, ensuring that they knew exactly what drug they were taking, and targeting recruitment at people who were dissatisfied with their current treatment or desperate for treatment. Trial protocols are, however, bound by strict methodological criteria and processes, including eligibility, randomization and blinding. Consequently, researchers cannot necessarily change study designs in the ways that participants suggested.

Misconceptions and misunderstandings about clinical trials occurred in our study, even though the focus group facilitators talked participants through example trials and answered any participant questions. Poor research literacy has been reported in other addiction pharmacological trials and is known to hinder trial recruitment\cite{10,24,27}. For example, one Australian survey revealed that many trial naïve injecting drug users did not understand key clinical trial concepts, such as blinding, placebo, equipoise and randomization, even after detailed verbal explanations. Meanwhile injecting drug users who demonstrated an understanding of placebo and double blinding were significantly more likely to perceive those concepts as acceptable compared with those who did not\cite{28}.

Ensuring that trial participants fully understand what will happen to them is an ethical requirement, especially vital given that financial incentives could attract otherwise reluctant people into pharmacological research. Participant understanding is clearly hindered by the complexity of trial designs and technical terminology. However, lack of trust in those associated with the research process (in this study, the pharmaceutical industry and treatment providers) will likely compound misunderstanding as well as deter engagement. This is a difficult problem to overcome but not insurmountable. Trial information does not have to be provided only via dense documents and formal information sheets delivered by researchers or clinicians. It can also be made available via informal media (such as video or social media) using accessible language and images which potential participants can view at the recruitment sites and elsewhere; enhanced consent forms or extended discussion during the consenting process\cite{29}; or interactive events hosted jointly with opioid users (including those who have already participated in similar trials) as part of a collaborative research effort\cite{30}.

To help improve future recruitment strategies we have used our findings to develop a checklist that researchers may wish to consider when designing new pharmacological trials for illicit opioid dependence (see Table 7). The checklist comprises 32 issues relating to the five domains identified in the focus groups: study burden; study drug; study design; study
population; and study relationships. We do not suggest that these are the only issues that researchers should consider and we recognise that some issues will be more relevant to some trials than others. We also note that the checklist is likely to require revision following further research. Nonetheless, it should offer a useful and immediate starting point.

TABLE 7

CONCLUSIONS

Recruiting to clinical trials of medications for illicit opioid use is a complex practical and ethical process. There are many pitfalls and barriers and whether or not any particular individual will enrol will depend on a multiplicity of factors. Although many early clinical trials (Phase 0-II) do not require large numbers of participants to be viable, RCTs need bigger sample sizes, are expensive if they over-run, and delay advances in treatment if they fail. Poor trial recruitment can also produce unrepresentative samples that undermine study results\(^{[12]}\).

Despite the various difficulties identified, the overall message from our research is positive. Firstly, participants in all six focus groups proactively identified strategies to encourage and facilitate trial recruitment, so demonstrating a basic desire to improve clinical pharmacological research. Secondly, some participants expressed a strong personal desire to participate in clinical trials without reimbursement or incentivisation, just because they wanted to help others. Thirdly, many reported that they could be encouraged to participate if the conditions and circumstances for involvement felt right. And fourthly, many more might be willing to participate if we become better at explaining trials to them, dispelling misconceptions, and increasing trust in the research process and the research establishment.
REFERENCES

1. Dole, V.P. (1965) Thoughts on narcotics addiction. *Bulletin of the New York Academy of Medicine*, 41(2): 211–213.

2. Dole, V.P. (1988) Implications of methadone maintenance for theories of narcotic addiction. *JAMA*, 260(20): 3025-3029.

3. Center for Substance Abuse Treatment. (2005) Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) Series 43. HHS Publication No. (SMA) 12-4214. Rockville, MD: Substance Abuse and Mental Health Services Administration.

4. World Health Organization (2017) WHO Model list of essential medicines 20th edition. Available at: http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf (accessed 9 October 2017) (Archived at http://www.webcitation.org/6u5fDQLej).

5. Sigmon, S.C. & Bigelow, G.E. (2017) Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. *Addiction*, 112(3): 386-387.

6. Food and Drug Administration (2017) The drug development process. Step 3: Clinical research. Available at: https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm (accessed 9 October 2017) (Archived at http://www.webcitation.org/6u5fLb6O8).

7. Treweek, S., Mitchell, E., Pitkethly, M., Cook, J., Kjeldstrom, M., Johansen, M., Taskila, T.K., Sullivan, F. Wilson, S., Jackson, C., Jones, R. & Lockhart, P. (2010) Strategies to improve recruitment to randomised controlled trials. *Cochrane Database of Systematic Reviews*, Issue 4. Art. No.: MR000013.

8. Watson, J.M. & Torgerson, D.J. (2006) Increasing recruitment to randomised trials: a review of randomised controlled trials. *BMC Medical Research Methodology*, 6: 34.
9. Sully, B.G., Julious, S.A. & Nicholl, J. (2013) A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. *Trials*, 14: 166.

10. Ashery, R.S. & McAuliffe, W.E. (1992) Implementation issues and techniques in randomized trials of outpatient psychosocial treatments for drug abusers: recruitment of subjects. *The American Journal of Drug and Alcohol Abuse*, 18(3): 305-329.

11. Demaret, I., Litran, G., Magoga, C., Deblire, C., Dupont, A., De Roubaix, J., Lemaitre, A. & Ansseau, M. (2014) Why do heroin users refuse to participate in a heroin-assisted treatment trial? *Heroin Addiction and Related Clinical Problems*, 16(3): 41-48.

12. Melberg, H.O. & Humphreys, K. (2010) Ineligibility and refusal to participate in randomised trials of treatments for drug dependence. *Drug and Alcohol Review*, 29(2): 193–201.

13. Oviedo-Joekes, E., Marchand, K., Lock, K., MacDonald, S., Guh, D. & Schechter, M.T. (2015) The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency. *Substance Abuse Treatment, Prevention, and Policy*, 10: 3.

14. Thomson, C.L., Morley, K.C., Teeson, M., Sannibale, C. & Haber, P.S. (2008) Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. *Drug and Alcohol Review*, 27(2): 115–122.

15. Bale, R.N., Van Stone, W.W., Kulda, J.M., Engelsing, T.M. & Zarcone, V.P. (1980) Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up. *Archives of General Psychiatry*, 37(2): 179–193.
16. Brooker, C., Peters, J., McCabe, C. & Short, N. (1999) The views of nurses to the conduct of a randomised controlled trial of problem drinkers in an accident and emergency department. *International Journal of Nursing Studies*, 36(1): 33–39.

17. Sheard, L., Tompkins, C.N.E., Wright, N.M.J. & Adams, C.E. (2006) Recruiting opiate users to a randomized controlled trial in primary care: a descriptive study of GP attitudes. *Primary Health Care Research and Development*, 7(2): 106–115.

18. Andreasson, S., Parmander, M. & Allebeck, P. (1990) A trial that failed, and the reasons why: comparing the Minnesota model with outpatient treatment and non-treatment for alcohol disorders. *Scandinavian Journal of Social Medicine*, 18(3): 221–224.

19. Chettiar, J., Lock, K., Oviedo-Joekes, E., Sievewright, K. & Schechter, M.T. (2008) The recruitment of participants to the Canadian heroin trial: Free heroin is not enough. In: 19th International Harm Reduction Conference, Barcelona, Spain. Poster presentation.

20. Gartry, C.C., Oviedo-Joekes, E., Laliberté, N. & Schechter, M. T. (2009) NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America. *Harm Reduction Journal*, 6: 2.

21. National Institute on Drug Abuse Clinical Trials Network (2008) Improving recruitment and retention R & R tips. Available at: https://www.drugabuse.gov/sites/default/files/files/NIDAR-n-Rweb.pdf (accessed 9 October 2017) (Archived at http://www.webcitation.org/6u5fRycDN).

22. Burlew, K., Larios, S., Suarez-Morales, L., Holmes, B., Venner, K. & Chavez, R. (2011) Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse’s Clinical Trials Network. *Cultural Diversity Ethnic Minority Psychology*, 17(4): 345-356.

23. Uhlmann, S., Milloy, M.J., Ahamad, K., Nguyen, P., Kerr, T., Wood, E. & Richardson, L. (2015) Factors associated with willingness to participate in a
pharmacologic addiction treatment clinical trial among illicit drug users. *The American Journal on Addictions*, 24(4): 368–373.

24. Slomka, J., Ratliff, E.A., McCurdy, S.A., Timpson, S. & Williams, M.L. (2008) Decisions to participate in research: views of underserved minority drug users with or at risk for HIV. *AIDS Care*, 20(10): 1224–1232.

25. Neale, J., Allen, D. & Coombes, L. (2005) Qualitative research methods within the addictions. *Addiction*, 100(11): 1584-1593.

26. Neale, J. (2016) Iterative categorization (IC): a systematic technique for analysing qualitative data. *Addiction*, 111(6): 1096-106.

27. Del Boca, F.K. & Darkes, J. (2007) Enhancing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment. *Addiction*, 102(8): 1194–1203.

28. Doab, A., Topp, L., Day, C.A., Dore, G.J. & Maher, L. (2009) Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. *Contemporary Clinical Trials*, 30(5): 431–435.

29. Nishimura, A., Carey, J., Erwin, P.J., Tilburt, J.C., Murad, M.H. & McCormick, J.B. (2013) Improving understanding in the research informed consent process: A systematic review of 54 interventions tested in randomized control trials. *BMC Medical Ethics*, 14(1): 28.

30. Neale, J., Bouteloup, A., Getty, M., Hogan, C., Lennon, P., Mc Cusker, M. & Strang, J. (2017) Why we should conduct research in collaboration with people who use alcohol and other drugs. *Addiction*, 112(12): 2084-2085.
Table 1: Participant details

| Demographic characteristics | FG\(^a\) 1 Oral methadone (n=4) | FG2 Oral methadone (n=8) | FG3 Buprenorphine tablets (n=8) | FG4 Buprenorphine tablets (n=8) | FG5 Injectable OAT\(^b\) (n=6) | FG6 Former OAT (n=6) | All (n=40) |
|----------------------------|---------------------------------|--------------------------|---------------------------------|---------------------------------|-----------------------------|---------------------|------------|
| **Gender**                 |                                 |                          |                                 |                                 |                             |                     |            |
| Male                       | 2 (50%)                         | 5 (63%)                  | 6 (75%)                         | 5 (63%)                         | 4 (67%)                     | 2 (33%)             | 26 (65%)   |
| Female                     | 2 (50%)                         | 3 (38%)                  | 2 (25%)                         | 3 (38%)                         | 2 (33%)                     | 2 (33%)             | 14 (35%)   |
| **Ethnicity**              |                                 |                          |                                 |                                 |                             |                     |            |
| White /White British\(^c\) | 2                               | 4                        | 6                               | 6                               | 5                           | 4                   | 27 (68%)   |
| Asian /Asian British       | 0                               | 0                        | 0                               | 0                               | 0                           | 0                   | 0 (0%)     |
| Black /Black British       | 2                               | 2                        | 1                               | 0                               | 0                           | 2                   | 7 (18%)    |
| Mixed or Multiple          | 0                               | 1                        | 1                               | 0                               | 0                           | 0                   | 3 (8%)     |
| Other                      | 0                               | 1                        | 0                               | 1                               | 0                           | 0                   | 3 (8%)     |
| **Age**                    |                                 |                          |                                 |                                 |                             |                     |            |
| Mean age (years)           | 49                              | 51                       | 46                              | 40                              | 56                          | 47                  | 48         |
| (range)                    | (42-59)                         | (43-58)                  | (33-55)                         | (34-47)                         | (47-66)                     | (39-58)             | (33-66)    |
| **Street opioid use**      |                                 |                          |                                 |                                 |                             |                     |            |
| Mean age of first use      | 23                              | 18                       | 24                              | 23                              | 18                          | 22                  | 21         |
| (range)                    | (16-33)                         | (14-22)                  | (14-31)                         | (14-35)                         | (15-27)                     | (15-32)             | (14-35)    |
| Mean duration of use       | 26                              | 33                       | 22                              | 17                              | 39                          | n/a                 | 27         |
| (range)                    | (22-30)                         | (25-39)                  | (2-37)                          | (0-33)                          | (27-50)                     | (0-50)              | (0-50)     |
| Current street opioid use  | 4 (100%)                        | 6 (75%)                  | 4 (50%)                         | 2 (25%)                         | 2 (33%)                     | n/a                 | 18 (53%)   |
| **Current treatment\(^d\)**|                                 |                          |                                 |                                 |                             |                     |            |
| None                       | 0                               | 0                        | 0                               | 0                               | 0                           | 0                   | 6 (15%)    |
| Buprenorphine (tablets)    | 0                               | 0                        | 0                               | 0                               | 0                           | 0                   | 16 (40%)   |
| Methadone (oral)           | 4                               | 8                        | 8                               | 0                               | 2                           | 0                   | 14 (35%)   |
| Methadone (injection)      | 0                               | 0                        | 0                               | 0                               | 2                           | 0                   | 2 (5%)     |
| Diamorphine (injection)    | 0                               | 0                        | 0                               | 0                               | 4                           | 0                   | 4 (10%)    |

\(^a\) Focus group; \(^b\) Opioid agonist treatment; \(^c\) 19 participants identified as ‘British’, 4 as ‘Italian’, 3 as ‘Irish’, and 1 as ‘European’; \(^d\) 2 participants were prescribed a combination of opioid medications (injectable + oral). The denominator used for the calculation of percentages across all subjects was n=40. Because two subjects from FG5 were included in the percentages for ‘Current treatment’ twice, the total percentage across all 40 subjects adds up to 105%.
Table 2: Study burden

| THEME                  | EXAMPLE QUOTATION                                                                 |
|------------------------|-----------------------------------------------------------------------------------|
| Discouraging participation |                                                                                  |
| i. Travel              | “Going to the chemist every day is a bind... It ties you to the chemist, you can’t go away.” (Female, FG2) |
| ii. Daily attendance requirements |                                                                                  |
| iii. Numerous study components |                                                                                  |
| iv. Toxicology testing | “You’ve got to come every week to have a drug test, which is a bit intrusive.” (Male, FG3) |
| v. Study length > 1 month |                                                                                  |
| Encouraging participation |                                                                                  |
| i. Local study sites | “Send a cab around… to pick you up and take you there.”                          |
| ii. Free transport    | (Male, FG3)                                                                      |
| iii. Attendance flexibility |                                                                                  |
| iv. Minimal tasks per treatment site visit | “Shorter trials are more acceptable to our community.” |
| v. Minimal study duration |                                                                                  |

(Male, FG5)
Table 3: Study drug

| THEME                           | EXAMPLE QUOTATION                                                                 |
|---------------------------------|-----------------------------------------------------------------------------------|
| **Discouraging participation**  |                                                                                  |
| i. Potential for withdrawal symptoms | “I’ve had bad, bad experiences with buprenorphine and Subutex. Because of that experience… I’d be scared to take a new trial drug now.” (Female, FG6) |
| ii. Interactions with regular medication |                                                                                  |
| iii. Previous adverse drug reaction |                                                                                  |
| iv. Dislike of the treatment drug |                                                                                  |
| v. First-in-human studies       |                                                                                  |
|                                 | “I don’t think people like the idea of… [being] a guinea pig.” (Male FG1)         |
| **Encouraging participation**   |                                                                                  |
| i. Availability of ‘rescue opioids’ | “There’d need to be… some kind of safeguard possibly, whether that be methadone or a morphine amp [ampoule] or something.” (Male, FG2) |
| ii. Control over study dose     |                                                                                  |
| iii. Direct access to medical care |                                                                                  |
| iv. Good information about trial drug |                                                                                  |
| v. Contract or ‘opt out’ clause | “I would want it written down, definitely, in black and white, that if I didn’t get on with it [trial medication] for whatever reason… I can go back to my previous prescription.” (Female, FG3) |
Table 4: Study design

| THEME                      | EXAMPLE QUOTATION                                                                                                                                 |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Discouraging participation | “Unless you incarcerate me or hold me in a controlled environment, I’m going to abuse your test. I’m going to go and use other drugs, so it’s going to affect it [the trial].” (Male, FG4) |
| i. Unclear study aim       | “Blinding wouldn’t work as people would be able to tell what medication they were getting from bodily functioning and how they are feeling.” (Female, FG2) |
| ii. Uncertain study feasibility |                                                                                                                                                      |
| iii. Randomization & blinding |                                                                                                                                                      |
| iv. Uncertainty over post-trial medication |                                                                                                                                                      |
| v. Unsuitable study site   |                                                                                                                                                      |
| Encouraging participation  | “I need to know about this medication. I need to have more information. About everything. About side effects, about everything.” (Male, FG1)         |
| i. Good study information  | “As long as there’s overseers and like doctors around, I wouldn’t mind trying it.” (Female, FG1)                                                        |
| ii. Controlled study environment |                                                                                                                                                      |
| iii. Reassurance about wrap-around support |                                                                                                                                                      |
Table 5: Study population

| THEME                           | EXAMPLE QUOTATION                                                                                                                                 |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Discouraging participation     |                                                                                                                                                 |
| i. People satisfied with current treatment | “People that are stable, they’ve stabilised their dose already, they’re not going to mess with it [current prescription].” (Male, FG5) |
|                                | “The risk of losing your existing drug, or even reducing, outweighs any financial [incentive].” (Male, FG4)                                        |
| Encouraging participation      |                                                                                                                                                 |
| i. People dissatisfied with current treatment | “I’d be always willing to try a new medication if it’s different from methadone.” (Male, FG1)                                                        |
| ii. People desperate for treatment | “People that are struggling to get into rehab... You’re in trouble, you’re on death’s door, you’ve scratched the bottom of the barrel, you need help. You’re probably going to go for things like this.” (Male, FG4) |
| THEME                        | EXAMPLE QUOTATION                                                                                                                                 |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| **Discouraging participation** |                                                                                                                                                 |
| i. Lack of trust in the pharmaceutical industry | “It’s about trust. Do I trust the medical industry?... At the end of the day they do make a lot of mistakes.” (Male, FG4) |
| ii. Lack of trust in the treatment system | “I don’t want to be getting letters from every other drug company in the country.” (Male, FG3)                                                |
| iii. Concerns about the confidentiality of personal data |                                                                                                                                                 |
| **Encouraging participation** |                                                                                                                                                 |
| i. Service user involvement | “I have to be compensated for my time, so money.” (Female, FG1)                                                                                   |
| ii. Persuasion from a trusted other |                                                                                                                                                 |
| iii. Cash payments           | “I’d do it to help others further down the line.” (Male, FG3)                                                                                   |
| iv. Non-cash payments        |                                                                                                                                                 |
| v. Altruism                  |                                                                                                                                                 |
Table 7: Checklist to increase potential participants’ willingness to enrol in clinical trials of pharmacological interventions for illicit opioid use - Version 1

| A. Study burden                                                                 |
|---------------------------------------------------------------------------------|
| 1. Minimise travel to the study site (distance and costs)                       |
| 2. Provide transport to the travel site if possible                             |
| 3. Consider home delivery of treatment medications or delivery by mobile treatment van |
| 4. Consider home completion of questionnaires or routine data collection/ trial monitoring |
| 5. Reimburse any travel costs                                                   |
| 6. Be flexible whenever possible in relation to attendance requirements at the study site |
| 7. Minimise the number of study tasks per visit to the study site                |
| 8. Avoid unnecessary toxicology screening                                        |
| 9. Keep the study duration as short as possible                                 |

| B. Study drug                                                                  |
|--------------------------------------------------------------------------------|
| 10. Provide clear, comprehensive and accessible information on the trial drug (including any research evidence, particularly the potential for withdrawal symptoms and side effects) |
| 11. Discuss potential drug/ medication interactions on an individual basis       |
| 12. Provide information on the availability of ‘rescue opioids’ if needed       |
| 13. Provide information on the availability of other medical care if needed     |
| 14. Offer participants a written contract or formal note on their medical records regarding ‘opting out’ or leaving the study and returning to their previous treatment |

| C. Study design                                                                 |
|--------------------------------------------------------------------------------|
| 15. Explain the study aims, methods, and recruitment strategy using a range of accessible media (in addition to any formal written study documentation) |
| 16. Provide a clear explanation of the reasons for blinding and randomization |
| 17. Provide clear information on what will happen at the end of the trial or if the participant leaves the trial |
| 18. Ensure the study site is comfortable and welcoming, and that potential participants are not likely to feel uncomfortable or stigmatized |
| 19. Ensure that participants have access to recreational activities during time spent at the study site (e.g. television, reading materials, computers, game consoles) |
| 20. Ensure that medical professionals and the availability of medical care are visible at study sites |
| 21. Provide participants with information about how the trial will or will not affect any other support or services they receive |

| D. Study population                                                             |
|--------------------------------------------------------------------------------|
| 22. Consider both scientific and ethical factors before targeting vulnerable or treatment dissatisfied subgroups of opioid users who might be more desperate for treatment and therefore more willing to participate |

| E. Study relationships                                                          |
|--------------------------------------------------------------------------------|
| 23. Consider the potentially negative impact on recruitment if the study is funded by the pharmaceutical industry or the treatment system is perceived as unstable |
| 24. Work collaboratively with current and former illicit opioid users in designing the trial (patient and public involvement is often a requirement of health funding bodies) |
| 25. Invite enthusiastic clinicians and illicit opioid users who have ever previously participated in research to talk about the study at events or via social media |
| 26. Invite enthusiastic clinicians and opioid users who have ever previously participated in research to help recruit to the study |
| 27. Offer financial payments that are respectful of the demands of participation and the level of risk involved |
| 28. If non-cash payments are offered, allow participants some choice regarding the type of voucher or incentive |
| 29. Consider whether, and if so how, payments (financial or non-cash) might bias the sample |
| 30. Provide reassurances about the confidentiality of the data                  |
| 31. Remember (and respect the fact) that some opioid users will participate in pharmacological trials for altruistic reasons |
| 32. Express thanks when opioid users agree to participate                       |